The Pharma Letter (registration) |
GSK gets European marketing rights for Nucala to treat asthma
The Pharma Letter (registration) UK drug major GlaxoSmithKline (LSE: GSK) said the European Commission has granted marketing rights for its drug Nucala (mepolizumab) as an add-on treatment for asthma. Nucala is now approved for use in the 31 European countries covered by the … EU OK for GSK's novel asthma biologic Nucala Now Available for Severe Asthma EU Grants Marketing Authorization to GSK's Nucala |
View full post on asthma – Google News